spacer
home > ict > spring 2018 > a new pathway
PUBLICATIONS
International Clinical Trials

A New Pathway

The average patient is becoming more tech-savvy and sophisticated as a consumer of healthcare. With smartphone adoption over 75% in the US and UK, owning a mobile device is the norm. However, the pharmaceutical industry is struggling to find patient-centric mobile solutions that keep pace with consumer expectations. A single clinical trial will commonly ask participants to use multiple systems and devices. While patient-facing technologies have proven to be valuable assets for engagement, retention, and data collection, offering too many point solutions burdens the patient, as it requires them to learn new software and devices and be compliant with unfamiliar technology.

A new pathway has been proposed that creates a more unified patient experience. A case example of a vendor collaboration that resulted in a single, mobile touchpoint for study patients is discussed, along with the associated benefits and weaknesses for the patient and sponsor.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jeff Lee is President eCOA and Patient Engagement, at Bracket, a clinical trial technology and speciality services provider. He joined Bracket in 2017, following the acquisition of mProve Health. As CEO of mProve, Jeff led the companies global growth, with its applications being used today by 18 of the top 20 pharma companies.
spacer
Jeff Lee
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) a subsidiary of WuXi AppTec and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement